Morocco Pharmaceuticals & Healthcare Report

Published 12 June 2015

  • 115 pages
  • Instant access to your report online and PDF format through your account library
  • Includes 3 free updated quarterly reports
$1,295.00
Morocco Pharmaceuticals & Healthcare Report

BMI View: Similar to other North African markets, Morocco's inclusion on PhRMA's Special 301 Submission for 2015 for intellectual property and pricing issues highlights the ongoing challenges that multinational drugmakers face in the market. However, we expect innovative drugmakers to continue seeking opportunities in Morocco, particularly with recent updates to the intellectual property law that highlights the country's commitment to improving the operating environment for multinationals.

Headline Expenditure Projections

  • Pharmaceuticals: MAD12.12bn (USD1.44bn) in 2014 to MAD12.99bn (USD1.35bn) in 2015; +7.2% in local currency terms and -6.5% in US dollar terms. Forecast revised upwards from last quarter.

  • Healthcare: MAD55.76bn (USD6.63bn) in 2014 to MAD60.00bn (USD6.22bn) in 2015; +7.6% in local currency terms and -6.1% in US dollar terms. Forecast revised downwards from last quarter.

Risk/Reward Index

In our latest proprietary Pharmaceutical Risk/Reward Index table, Morocco continues to be viewed as a moderately attractive pharmaceutical market in the Middle East and Africa region, from a longer-term perspective. Morocco ranks 14th in the region out of the 31 countries assessed, with a score of 43.0 out of 100. The market's constraints include low per capita consumption and an underdeveloped reimbursement system, although such factors are to a degree offset by a relatively predictable operating environment.

Key Trends And Developments

May 2015

Moroccan health minister El Hussein Louardi, has voiced his support for abortions in the country during an interview with French-speaking magazine Telquel. 'I think it is absolutely necessary to legalize abortion, because it is not only a medical problem but also a social problem,' the minister told the magazine. Around 600 woman and girls are reported to have abortions illegally every day; a further 200 are carried out by non-medical practices, according to The Moroccan Association for the Fight against...

BMI Industry View
7
SWOT
9
Political
11
Economic
13
Operational Risk
14
Industry Forecast
16
Pharmaceutical Market Forecast
16
Table: Pharmaceutical Sales, Historical Data And Forecasts (Morocco 2011-2019)
18
Healthcare Market Forecast
19
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Morocco 2011-2019)
21
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Morocco 2011-2019)
21
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Morocco 2011-2019)
21
Prescription Drug Market Forecast
22
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Morocco 2011-2019)
23
Patented Drug Market Forecast
24
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Morocco 2011-2019)
25
Generic Drug Market Forecast
26
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Morocco 2011-2019)
28
OTC Medicine Market Forecast
29
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Morocco 2011-2019)
30
Pharmaceutical Trade Forecast
31
Table: Pharmaceutical Trade Data And Forecasts (Morocco 2013-2019)
33
Table: Pharmaceutical Trade Data And Forecasts local currency (Morocco 2013-2019)
33
Key Risks To BMI's Forecast Scenario
34
Macroeconomic Forecasts
35
Economic Analysis
35
Expenditure Breakdown
37
Table: Various Countries, Real GDP Growth, % chg y-o-y
42
Table: Economic Activity (Morocco 2010-2019)
42
Industry Risk Reward Indices
43
Middle East And Africa Risk/Reward Index
43
Morocco Risk/ Reward Index
51
Rewards
51
Risks
52
Market Overview
54
Industry Trends And Developments
55
Epidemiology
55
Healthcare Sector
57
Table: Healthcare Resources (Morocco 2009-2014)
61
Table: Healthcare Personnel (Morocco 2009-2014)
61
Table: Healthcare Activity (Morocco 2009-2014)
62
Healthcare Insurance
62
Recent Health Insurance Developments
64
Research & Development
67
Clinical Trials
68
Regulatory Development
69
Intellectual Property Regime
70
Pricing Regime
70
Reimbursement Regime
73
Competitive Landscape
75
Pharmaceutical Industry
75
Table: Morocco's Select Pharmaceutical Industry Indicators
75
Table: Members Of MIS, 2011
76
Table: Members Of AMIP, 2011
77
Domestic Pharmaceutical sector
77
Foreign Pharmaceutical Companies
78
Pharmaceutical Wholesale
81
Pharmaceutical Retail
82
Company Profile
83
Sothema
83
Laprophan
86
Promopharm
89
Sanofi
91
Pfizer
95
GlaxoSmithKline
98
Ranbaxy
100
Demographic Forecast
103
Demographic Outlook
103
Table: Population Headline Indicators (Morocco 1990-2025)
104
Table: Key Population Ratios (Morocco 1990-2025)
104
Table: Urban/Rural Population & Life Expectancy (Morocco 1990-2025)
105
Table: Population By Age Group (Morocco 1990-2025)
105
Table: Population By Age Group % (Morocco 1990-2025)
106
Glossary
108
Methodology
110
Pharmaceutical Expenditure Forecast Model
110
Healthcare Expenditure Forecast Model
110
Notes On Methodology
111
Risk/Reward Index Methodology
112
Index Overview
113
Table: Pharmaceutical Risk/Reward Index Indicators
113
Indicator Weightings
114

The Morocco Pharmaceuticals & Healthcare Report features BMI Research's forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Morocco Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Morocco pharmaceutical and healthcare industry.

Key Benefits

  • Benchmark BMI's pharmaceutical and healthcare market forecasts for Morocco, to test other views - a key input for successful budgeting and strategic business planning in the Moroccan pharmaceutical and healthcare market.
  • Target business opportunities and risks in the Moroccan pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Morocco.
  • Assess the activities, strategy and market position of your competitors using our company profiles (including SWOTs, KPIs and latest activity) and competitive landscape tables.

Coverage

BMI Industry View

An at-a-glance perspective on the latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The pharmaceuticals and healthcare SWOT outlines strategic factors that affect the basic assumptions underpinning BMI’s forecast analysis, and taken together with BMI’s political, economic and business environment SWOTs, it gives a complete overview of market climate.

BMI Industry Forecast Scenario

Industry forecasts to end-2019 for all key indicators, supported by explicit assumptions, plus analysis of key downside risks to the main forecasts:

  • Healthcare: Total healthcare expenditure (USDbn), healthcare expenditure (% of GDP), healthcare expenditure per capita (USD), hospital beds, doctors, and birth & mortality rates (all per ‘000 population).
  • Pharmaceutical Market: Drug expenditure in USDbn, % of GDP and per capita (USD).
  • Patented Drug Market: Prescription drug sales (USDbn & % of total sales).
  • Generic Drug Market: Generic product sales (USDbn), generic sales (% of total sales).
  • OTC Drug Market: OTC sales (USDbn & % of total sales).
  • Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against USD, government expenditure and external debt.

BMI’s Pharmaceuticals and Healthcare Risk Reward Index

BMI’s Risk Reward Index provides investors (both national and multinational) looking for opportunities in the region with a clear country-comparative assessment of the market’s risks and potential rewards. Each of the country markets are scored using a sophisticated model that includes more than 40 industry, economic and demographic data points to provide indices of highest to lowest appeal to investors, with each position explained.

Market Summary

A snapshot of key market characteristics, including total size of the pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape

Industry Developments

A focus on government healthcare reforms, epidemiological trends, mergers and acquisitions, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

Regulatory Regime

Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as analysis of the overall regulatory burden.

Competitive Landscape

The competitive landscape section provides comparative company analyses and index by USD sales and % share of total sales – for the total pharmaceutical sector, as well as the OTC, generics and distribution sub-sectors.

Company Profiles*

Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI’s industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.

*Company profiles are not available for every country. Those reports instead contain information on the current activities of prominent companies operating in the market.

secure
Benefit from discounts when you add multiple products to your basket
2 Products SAVE 10%
3 Products SAVE 15%
4 Products SAVE 20%
5 Products SAVE 25%
6 Products SAVE 30%
7 - 20 Products SAVE 35%
21 Products or more SAVE 40%